Mayo Clinic proceedings
-
Mayo Clinic proceedings · Oct 2006
Randomized Controlled Trial Multicenter StudyAssessing the ability of topiramate to improve the daily activities of patients with migraine.
To assess the impact of topiramate on the daily activities of patients with migraine. ⋯ Patient-reported migraine-specific outcomes measured by the MSQ-RR and MSQ-RP domains improved significantly for those receiving topiramate (all doses) vs placebo. The SF36-RP domain scores improved significantly for patients receiving 100 or 200 mg/d of topiramate. Improvements in all 4 prospectively selected MSQ and SF-36 domains were significantly correlated with decreases in mean monthly migraine frequency.
-
Mayo Clinic proceedings · Jul 2006
Multicenter Study Comparative StudyAdult intensive care unit use at the end of life: a population-based study.
To determine population-based rates of intensive care unit (ICU) use at the end of life in adults and describe demographic and clinical variation in end-of-life ICU use. ⋯ The rate of ICU use at the end of life Increases significantly with age and with the number of coexisting chronic illnesses.
-
Mayo Clinic proceedings · Jan 2006
Randomized Controlled Trial Multicenter StudyRopinirole in the treatment of patients with restless legs syndrome: a US-based randomized, double-blind, placebo-controlled clinical trial.
To assess the efficacy, safety, and tolerability of the dopamine agonist ropinirole in the treatment of patients with moderate to severe primary restless legs syndrome (RLS). ⋯ This study confirms that ropinirole improves RLS symptoms and subjective measures of sleep, quality of life, and anxiety and that it is generally well tolerated.
-
Mayo Clinic proceedings · May 2005
Randomized Controlled Trial Multicenter Study Comparative Study Clinical TrialA community-based, randomized trial of ezetimibe added to statin therapy to attain NCEP ATP III goals for LDL cholesterol in hypercholesterolemic patients: the ezetimibe add-on to statin for effectiveness (EASE) trial.
To determine the extent of reduction in low-density lipoprotein cholesterol (LDL-C) level and improvement in National Cholesterol Education Program Adult Treatment Panel III (NCEP ATP III) LDL-C goal attainment when ezetimibe was added to ongoing statin therapy in a diverse population of community-based patients. ⋯ Across multiple subgroups, ezetimibe added to statin therapy consistently produced significant additional improvements in LDL-C levels and goal attainment, as well as in other lipoproteins, compared with addition of placebo. The addition of ezetimibe to statin therapy should be considered for patients not achieving their NCEP ATP III LDL-C goals while receiving statin therapy alone.
-
Mayo Clinic proceedings · Apr 2005
Randomized Controlled Trial Multicenter Study Comparative Study Clinical TrialEvaluation of the comparative efficacy of etoricoxib and ibuprofen for treatment of patients with osteoarthritis: A randomized, double-blind, placebo-controlled trial.
To directly compare the efficacy and safety of etoricoxib, 30 mg once daily, ibuprofen, 800 mg 3 times daily, and placebo for treatment of osteoarthritis (OA) of the hip and knee. ⋯ For patients with OA, treatment with etoricoxib, 30 mg/d, is well tolerated and provides sustained clinical effectiveness that is superior to placebo and comparable to ibuprofen, 2400 mg/d.